References used across the site

DailyMed: Ozempic prescribing information

Primary label source for severe gastrointestinal adverse reactions, retinopathy language, and boxed-warning statements.

FDA label: Wegovy (semaglutide)

Current FDA label revised February 2026 for severe GI reactions, pregnancy language, diabetic retinopathy monitoring, thyroid boxed-warning language, and removal of suicidal-behavior language.

NIDDK: Gastroparesis overview

NIH patient overview explaining delayed gastric emptying, symptoms, diagnosis, and treatment topics.

NIDDK: Symptoms & causes of gastroparesis

NIH reference for common symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain.

NIDDK: Eating, diet, & nutrition for gastroparesis

NIH guidance on smaller meals, low-fat and low-fiber foods, liquids, and hydration strategies when symptoms are active.

NIDDK: Symptoms & causes of pancreatitis

NIH overview of pancreatitis symptoms, common causes, and warning signs that need prompt medical attention.

NIDDK: Diagnosis of pancreatitis

NIH overview of how clinicians evaluate pancreatitis, including symptoms, lab work, imaging, and differential diagnosis.

MedlinePlus: Intestinal obstruction and ileus

NIH medical encyclopedia overview defining intestinal obstruction and ileus, with symptoms and complication risks.

MedlinePlus: Dehydration

NIH overview of dehydration symptoms, emergency warning signs, and common testing or treatment basics.

NIDDK: Symptoms & causes of intestinal pseudo-obstruction

NIH reference explaining intestinal pseudo-obstruction symptoms, including abdominal pain, bloating, nausea, vomiting, and inability to pass stool or gas in acute colonic pseudo-obstruction.

NIDDK: Symptoms & causes of gallstones

NIH reference on gallbladder attacks, upper-right abdominal pain, nausea and vomiting, jaundice, fever, and gallstone complications.

MedlinePlus: Semaglutide injection drug information

NIH drug reference for common side effects, serious warnings, and when patients should call a clinician.

NEI: Diabetic retinopathy

National Eye Institute overview of diabetic retinopathy, symptoms, risk of vision loss, and treatment basics.

NEI: Get a dilated eye exam

National Eye Institute guidance on dilated eye exams and why they matter even before symptoms are obvious.

NIAMS: Gout

NIH overview of gout, uric-acid crystal buildup, symptoms, diagnosis, risk factors, and treatment options.

PubMed: URISEMA real-world semaglutide study

Recent retrospective study reporting a modest decrease in serum urate after 12 months of semaglutide treatment in adults with type 2 diabetes.

HHS: Your medical records

HHS patient guidance on the right to inspect, review, and receive copies of medical and billing records.

HHS OCR: Individuals' right under HIPAA to access health information

HHS OCR guidance explaining that designated record sets can include medical records, billing records, lab reports, imaging, and other records used to make decisions about an individual.

JPML: Pending MDL dockets by actions pending (April 1, 2026)

JPML statistics report showing active GLP-1 MDL counts, including MDL 3094 for GI claims and MDL 3163 for NAION claims.

JPML: MDL 3163 transfer order

December 15, 2025 transfer order creating the GLP-1 NAION multidistrict litigation and describing the common factual questions in those cases.

JAMA Ophthalmology: semaglutide and NAION cohort study

Peer-reviewed ophthalmology study examining semaglutide exposure and non-arteritic anterior ischemic optic neuropathy.

EMA: NAION is a very rare side effect of semaglutide medicines

European Medicines Agency communication concluding that NAION is a very rare semaglutide side effect and recommending product-information updates.

FDA: removal of suicidal-behavior and ideation warning from GLP-1 RA obesity labels

January 13, 2026 FDA safety communication requesting removal of suicidal-behavior language after a review found no increased risk.

Levin Papantonio: public GLP-1 intake criteria PDF

Public law-firm intake sheet showing how at least one active GLP-1 firm screens for drug, timing, diagnosis, ER or hospital care, and representation conflicts.

ClinicalTrials.gov: NCT06292065

Study tracking gastric contents in patients on semaglutide therapy, useful for monitoring how the gastric-retention issue is evolving.

ClinicalTrials.gov: NCT07156591

Study on neuropathy and semaglutide-induced gastric retention, relevant to the delayed-emptying research topic.

ClinicalTrials.gov: NCT07242534

Trial examining semaglutide and embryo quality in IVF patients, relevant to the pregnancy and reproductive-planning topic.

FDA: action against non-FDA-approved GLP-1 drugs

February 6, 2026 FDA statement on enforcement against non-FDA-approved compounded GLP-1 products and misleading marketing claims.

FDA: counterfeit Ozempic found in the U.S. drug supply chain

FDA safety page updated December 5, 2025 describing seized counterfeit Ozempic, how the fake pens were identified, and why patients should use state-licensed pharmacies.

FDA: counterfeit medicine

FDA overview explaining what counterfeit medicines are, possible warning signs, and why online or unauthorized sellers create a different risk picture.

FDA: concerns with unapproved GLP-1 drugs used for weight loss

FDA page on compounded, fraudulent, and otherwise unapproved GLP-1 products, including shipping, dosing, and labeling concerns.

DailyMed: BYETTA (exenatide) injection

Current Byetta source for acute pancreatitis, kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity, and thrombocytopenia warnings.

FDA label: BYDUREON (exenatide extended-release)

Current Bydureon label for the thyroid boxed warning plus acute pancreatitis, kidney injury due to volume depletion, severe GI reactions, gallbladder disease, and thrombocytopenia warnings.

FTC: Health Products Compliance Guidance

Federal Trade Commission guidance on keeping health-related claims truthful, qualified, and supported.